Skip to main content

Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose.

Publication ,  Journal Article
Kim, CY; Heye, T; Bashir, MR; Gebhard, TA; Merkle, EM
Published in: J Comput Assist Tomogr
2013

OBJECTIVE: The objectives of this study were to evaluate the feasibility of gadofosveset-enhanced magnetic resonance angiography (MRA) of the thoracic vasculature in the equilibrium phase and to determine the impact of gadofosveset dose on imaging quality. METHODS: Thirty healthy volunteers were randomized to receive a dose of 0.03, 0.02, or 0.01 mmol/kg of gadofosveset for MRA at 3 T in the equilibrium phase. Two radiologists assessed the central veins, the pulmonary arteries, and the thoracic aorta. Quantitative assessments were also performed. RESULTS: At 0.03 and 0.02 mmol/kg, all vessel segments were rated as adequate. At a dose of 0.01 mmol/kg, less than 10% of vascular segments were collectively rated as inadequate. The signal-to-noise ratio and contrast-to-noise ratio were significantly lower in all segments at 0.01 mmol/kg compared with higher doses. CONCLUSIONS: Gadofosveset-enhanced MRA of the thoracic vessels in the equilibrium phase in healthy volunteers resulted in adequate vessel visualization, even when dose reduction was performed.This trial was registered with clinicaltrials.gov, identifier NCT01431300.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Comput Assist Tomogr

DOI

EISSN

1532-3145

Publication Date

2013

Volume

37

Issue

5

Start / End Page

732 / 736

Location

United States

Related Subject Headings

  • Young Adult
  • Thorax
  • Sensitivity and Specificity
  • Reproducibility of Results
  • Radiography, Thoracic
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Male
  • Magnetic Resonance Angiography
  • Image Enhancement
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kim, C. Y., Heye, T., Bashir, M. R., Gebhard, T. A., & Merkle, E. M. (2013). Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose. J Comput Assist Tomogr, 37(5), 732–736. https://doi.org/10.1097/RCT.0b013e318299dde9
Kim, Charles Y., Tobias Heye, Mustafa R. Bashir, Thomas A. Gebhard, and Elmar M. Merkle. “Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose.J Comput Assist Tomogr 37, no. 5 (2013): 732–36. https://doi.org/10.1097/RCT.0b013e318299dde9.
Kim CY, Heye T, Bashir MR, Gebhard TA, Merkle EM. Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose. J Comput Assist Tomogr. 2013;37(5):732–6.
Kim, Charles Y., et al. “Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose.J Comput Assist Tomogr, vol. 37, no. 5, 2013, pp. 732–36. Pubmed, doi:10.1097/RCT.0b013e318299dde9.
Kim CY, Heye T, Bashir MR, Gebhard TA, Merkle EM. Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose. J Comput Assist Tomogr. 2013;37(5):732–736.

Published In

J Comput Assist Tomogr

DOI

EISSN

1532-3145

Publication Date

2013

Volume

37

Issue

5

Start / End Page

732 / 736

Location

United States

Related Subject Headings

  • Young Adult
  • Thorax
  • Sensitivity and Specificity
  • Reproducibility of Results
  • Radiography, Thoracic
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Male
  • Magnetic Resonance Angiography
  • Image Enhancement